Business
Travere Therapeutics to Present Abstracts at American Society of Nephrology Kidney Week 2021
SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present
About this update from Travere Therapeutics, Inc.
[{"type":"text","content":"SAN DIEGO, Nov. 02, 2021 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (NASDAQ: TVTX) today announced that the Company and its collaborators will present abstracts based on non-clinical data describing the potential for sparsentan, an investigational product candidate, to protect kidney function in models of rare glomerular diseases, including a potential anti-inflammatory role in IgA nephropathy (IgAN), at the American Society of Nephrology (ASN) Kidney Week 2021. Sparsentan is a Dual Endothelin Angiotensin Receptor Antagonist (DEARA) currently in Phase 3 clinical development for the treatment of IgAN and focal segmental glomerulosclerosis (FSGS). The company will also present data from natural history studies highlighting the challenges associated with managing IgAN and FSGS, as well as data indicating poor renal survival in children and adults living with these rare kidney disorders. In addition, an analysis of the association between achieving complete or partial remission of proteinuria and delaying the progression to end-stage kidney disease (ESKD) in FSGS will be presented. ASN Kidney Week 2021 is being held virtually November 4-7, 2021. All ePosters will be made available to ASN Kidney Week 2021 participants on November 4, 2021 at 10:00 a.m. PT, and will be accessible on-demand through January 7, 2022. The Dual Endothelin Angiotensin Receptor Antagonist (DEARA) Sparsentan Protects from Glomerular Hypercellularity and Associated Immune/Inflammatory Gene-Network-Activity in a Model of IgA Nephropathy (IgAN)ePoster #: PO1454Session: Glomerular Diseases: Immunology and Inflammation in IgANP, C3GP, TMA, and Nephrotic Diseases Clinicopathological Characteristics of Adult IgA Nephropathy: A Retrospective Cohort StudyePoster #: PO1576Session: Glomerular Diseases: Clinicopathological Features and Outcomes in IgAN, Lupus Nephritis, and Vasculitis Natural History of IgA Nephropathy: Analysis of a UK National RaDaR IgA Nephropathy CohortePoster #: PO1577Session: Glomerular Diseases: Clinicopathological Features and Outcomes in IgAN, Lupus Nephritis, and Vasculitis An International Delphi Survey on IgA Nephropathy: Results from the DEFINE Physicians Study ePoster #: PO1641Session: Glomerular Diseases: Treatment and Outcomes Proteinuria End Points and Association With Renal Survival in FSGS: Analysis of the UK National RaDaR Idiopath...